Cholangiocarcinoma epidemiology and demographics

Xyz Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Xyz from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cholangiocarcinoma epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cholangiocarcinoma epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cholangiocarcinoma epidemiology and demographics
CDC on Cholangiocarcinoma epidemiology and demographics
Cholangiocarcinoma epidemiology and demographics in the news
Blogs on Cholangiocarcinoma epidemiology and demographics
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Cholangiocarcinoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [2] Suveenkrishna Pothuru, M.B,B.S. [3]

Epidemiology and Demographics

Incidence

• The incidence of cholangiocarcinoma is approximately 1-2 per 100,000 individuals in the United States.
• The highest annual incidences of cholangiocarcinoma is 5.5 cases per 100,000 people in Japan, and 7.3 cases per 100,000 people in Israel.

Prevalence

• The prevalence of cholangiocarcinoma is approximately 0.01% to 0.46% per 100,000 individuals.
• The prevalence of cholangiocarcinoma in patients with primary sclerosing cholangitis may be as high as 30%, based on autopsy studies.

Case-fatality rate/Mortality rate

• The mortality rate for intrahepatic cholangiocarcinoma among men increased from 0.17 to 0.78 per 100,000 in period of 1975-1979 to 1993-1997.
• The mortality rate for intrahepatic cholangiocarcinoma among women women increased from 0.12 to 0.57 per 100,000 in period of 1975-1979 to 1993-1997.

Age

• Patients of all age groups may develop cholangiocarcinoma.
• The median age at the time of cholangiocarcinoma diagnosis is 70-80 years, except in patients with bile duct cystic disorders.
• Bile duct cystic disorders usually develop cholangiocarcinoma much earlier, between 30 and 40 years.

Race

• Cholangiocarcinoma usually affects individuals of the American Indian, Alaska Natives and Asian and Pacific Islanders race.

Gender

• Cholangiocarcinoma is more common in males than in females.

Region

• The majority of cholangiocarcinoma cases are reported in North America, Europe, Asia, and Australia.